Summary. Ergocryptine (2 mg/kg) caused short-and long-term reduction of prolactin secretion in rats experiencing concurrent lactation and pregnancy. The long-term effects of the drug lasted at least 60 days and resulted in reduced milk secretion and termination of pregnancy. Prolactin replacement therapy at a low dose (5 i.u./day) was unsuccessful in overcoming these effects but a higher dose (up to 60 i.u./day) increased milk production and maintained pregnancy. One possible explanation of these results is that prolactin, rather than the suckling stimulus, was responsible for the suppression of oestrous cycles, because ergocryptine brought about a resumption of oestrous vaginal smears in all treated rats in spite of continued suckling.
Introduction
The ergot alkaloid, ergocornine, can inhibit prolactin release from cultured pituitary halves (Mettes et al, 1972) . This inhibition of prolactin release is associated with a rise in the pituitary prolactin content (Lu, Koch & Mettes, 1971) , suggesting that ergot alkaloids, which are known to act as dopamine agonists, are probably acting at the pituitary level. Ergocryptine is a closely related ergot alkaloid and has been used extensively to terminate both pregnancy and lactation in the rat (Shelesnyak, 1957; Dohler & Wuttke, 1974; Lu et al., 1976) . Most studies which have been made of ergocryptine suppression of prolactin secretion have concentrated on the shortterm effects, and the present study was carried out to investigate the long-term effects of ergocryptine on concurrent pregnancy and lactation, with particular reference to the role of prolactin in pregnancy.
Materials and Methods
Mature female inbred Wistar rats weighing 180-250 g were paired and allowed to complete a normal pregnancy (22 ±0-16 (Fluckiger, Marko, Doepfner & Niederer, 1976) . It also produced embryonic résorption, as previously described for non-lactating pregnant rats (Shelesnyak, 1957) . However, the drug produced unusual long-term effects lasting up to 60 days in some rats.
The results reported in this study suggest that termination of pregnancy is brought about by means of this long-term effect on prolactin secretion rather than the immediate effect of the drug, since a low dose of prolactin overcame the initial effect, but was not able to prevent abortion or the long-term effect on growth rate of the young. A second possibility is that the secondary drop in prolactin levels might not be due to ergocryptine injection but to a reduction in suckling intensity. This may also explain discrepancies between the present work and that of Lu et al. (1976) who showed no return to oestrous cycles until 11 days after the start of continuous 2-bromo-a-ergocryptine treatment. There are a number of objections to this second possibility. Although the young did not receive much milk during the 24 h immediately after injection, they were able to recover well enough to maintain growth rates similar to those of controls for several days. This would suggest that a subsequent drop in growth rate would not occur unless there was a drop in milk production. In addition, those young which were growing fastest showed a similar drop in growth rate despite the fact that they still continued to gain consider¬ able weight, and in some litters so many deaths occurred that the litter had to be replaced to maintain the suckling stimulus.
Detrimental effects of the drug on both pregnancy and lactation lasted up to 2 months and yet no long-term effects of the drug have been previously described at this dose (and higher) in the rat (Griffith, 1974) , monkey (Griffith, 1976) or dog (Griffith & Richardson, 1975) . All these studies were performed using a 2-bromo-a-ergocryptine (CB 154) and the drugs are known to have different effects (Fluckiger & Wagner, 1968 (Arai, Suzuki & Masuda, 1972; Macleod & Lehmeyer, 1972; Sinha, Selby & Vanderlaan, 1974) . It seems unlikely that this ergocryptine-receptor complex would persist for several days and this therefore suggests an inhibition of the synthetic process or long-term alteration of the eta cell membrane. Evidence suggests that, as the pituitary recovers from the initial effects of ergocryptine treatment, long-term alteration of the membrane does not occur.
There is some evidence, although not detailed, from other studies supporting the suggestion that ergocryptine suppresses prolactin production on a long-term basis. Yanai & Nagasawa (1970) have shown that ergocryptine can block the development of hyperplastic alveolar nodules in mice. Similarly Quadri & Mettes (1971) have reported suppressed growth of spontaneous mammary tumours in old female rats. Smith, Beck, Convey & Tucker (1974) have shown that ergocryptine inhibition of prolactin can last up to 5 days following two consecutive injections.
Obviously the long-term effects of ergocryptine in female rats require further study.
